Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00628472 · ClinicalTrials.gov registry record · NA

Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort

A NA study of Pain, sponsored by Henry Ford Health System.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT00628472: Completed NA study of Pain, sponsored by Henry Ford Health System.

NCT00628472 is a NA study of Pain that has completed, run by Henry Ford Health System. The registered enrollment target is 21 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00628472, a NA study of Pain, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

This single blinded randomized pilot study was performed on 21 Caucasian females to determine if injections through follicular openings were less painful than traditional injections for cosmetic botulinum toxin type A injections.

Conditions Studied

Interventions

  • DRUG botulinum type a

Study Locations (1)

Michigan

  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2007-01
Est. Completion 2007-05
Phase NA
Henry Ford Health System

234 total trials

What the finished NCT00628472 record still lists

NCT00628472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which botulinum type a is the first listed.

NCT00628472 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT00628472 about?

NCT00628472 is a clinical study titled "Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort". This single blinded randomized pilot study was performed on 21 Caucasian females to determine if injections through follicular openings were less painful than traditional injections for cosmetic botulinum toxin type A injections.

What is the current status of trial NCT00628472?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2007-01. Estimated completion is 2007-05.

What conditions does trial NCT00628472 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT00628472?

The interventions under investigation include: botulinum type a (DRUG).

Who is sponsoring clinical trial NCT00628472?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00628472 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00628472's enrollment target sits among peer trials

21 337th of 374 higher than 38 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00628472, the US trial registry maintained by the National Library of Medicine. NCT00628472 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.